<DOC>
	<DOCNO>NCT00402610</DOCNO>
	<brief_summary>INTRODUCTION . To evaluate efficacy three regimens prophylactic therapy tuberculosis HIV-infected patient anergy . METHODS . Prospective , multi-center , randomize , comparative , open clinical trial . Anergy define absence induration response three antigen ( PPD , Candida albicans parotiditis antigen ) apply Mantoux method . Patients randomize one follow prophylactic treatment group : isoniazid six month ( 6H ) , rifampin plus isoniazid three month ( 3RH ) , rifampin plus pyrazinamide two month ( 2RZ ) treatment ( NT ) . After completion treatment , patient follow two year .</brief_summary>
	<brief_title>A Randomized Trial Three Regimens Prevent Tuberculosis HIV-Infected Patients With Anergy</brief_title>
	<detailed_description>This study control , open , randomize , multi-center clinical trial . The study authorize Clinical Research Ethics Committee participate center inform write consent obtain patient include . The cutaneous anergy define absence reaction ( 0 mm ) skin reactivity test tuberculin , Candida albicans , parotiditis antigens 72 hour inoculation . The patient randomzed one follow four group : isoniazid 6 month ( 6H ) , rifampin plus isoniazid 3 month ( 3RH ) , rifampin plus pyrazinamide 2 month ( 2RZ ) treatment ( NT ) . All participate subject underwent basal study include clinical epidemiological history , chest x-ray , hemogram , analysis serum creatinine concentration , uric acid , AST , ALT , alkaline phosphatase , total bilirubin , well CD4+ T-lymphocyte count.During prophylactic treatment , patient evaluate every 15 day first two month monthly thereafter . At check-up determine whether patient follow treatment properly whether adverse effect . Therapeutic completion define take least 80 % total prescribed dosages.Chemoprophylaxis discontinue whenever patient request follow reason : appearance Grade 3 4 side effect could attribute drug use study ; increase AST and/or ALT value three time basal value ; development TB ; diagnosis disease make interruption treatment advisable .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<criteria>HIV infection confirm ELISA Western blot Age 18 65 year Life expectancy great two year Cutaneous anergy define absence reaction ( 0 mm ) skin reactivity test tuberculin , Candida albicans , parotiditis antigens 72 hour inoculation . Presence active tuberculosis Background previous antituberculosis therapy chemoprophylaxis Presence symptom sign suggest pulmonary extrapulmonary tuberculosis History hypersensitivity drug use study ( isoniazid , rifampin pyrazinamide ) Aspartateaminotransferase and/or alanineaminotransferase plasma concentration equal four time normal value , total bilirubin 2 mg/ml , and/or creatinine 2 mg/ml Pregnancy Undergoing treatment incompatible drug use study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>HIV</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>Chemoprophylaxis</keyword>
	<keyword>Anergy</keyword>
	<keyword>AIDS</keyword>
</DOC>